Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities

Florence Paula Madorsky-Rowdo1, María Laura Lacreu1 and José Mordoh1,2 *

1 Laboratorio de Cancerología, Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina
2 Centro de Investigaciones Oncológicas, Fundación Cancer and Instituto Alexander Fleming, Buenos Aires, Argentina

Edited by: Brian J. Czerniecki, University of Pennsylvania, USA
Reviewed by: Fabio Bagnoli, Novartis Vaccines, Italy Sylvie Fourmet, Strasbourg University, France
*Correspondence: José Mordoh, Laboratorio de Cancerología, Fundación Instituto Leloir, Av. Patricias Argentinas 435, 1405 Buenos Aires, Argentina. e-mail: jr.mordoh@leloir.org.ar

To endow the immune system with the capacity to fight cancer has always attracted attention, although the clinical results obtained have been until recently disappointing. Cutaneous melanoma is a highly immunogenic tumor; therefore most of the attempts to produce cancer vaccines have been addressed to this disease. New advances in the comprehension of the mechanisms of antigen presentation by dendritic cells, in the immune responses triggered by adjuvants, as well as the understanding of the role of immunosuppressor molecules such as cytotoxic T-lymphocyte antigen-4 (CTLA-4), which led to the recent approval of the anti-CTLA-4 monoclonal antibody ipilimumab, have opened new hopes about the installment of immunotherapy as a new modality to treat cancer.

Keywords: cancer vaccines, immunotherapy, CTLA-4, melanoma

The human immune system is highly elaborated, with a diversity of stop and go mechanisms necessary to accomplish different tasks, encompassing clear “stop” situations, such as those needed to avoid fetal rejection during pregnancy, and permanent “go” status, necessary to combat infections by virus, bacteria, or fungi. Both mechanisms are in place or may be activated in a healthy organism, and distinction of “self” and “foreign” is essential to accomplish these tasks. Being cancer a disease generated by autologous cells, is it possible to teach the organism to fight it? In this review, which does not intend to be exhaustive, we shall discuss some of the most explored fields of research which aim to fight cancer through stimulating or inhibiting some specific targets of the immune system.

IMMUNE STIMULATION BY CANCER VACCINES

The rationale of using therapeutic vaccines in cancer began in the 1950s, when the fact that tumors express specific antigens (Ag) was demonstrated (Foley, 1953; Prehn and Main, 1957). Thus, immunity to cancer might be acquired, and the idea of developing cancer vaccines started. Most of the work in this field was performed on cutaneous melanoma (CM), which originates from melanocytes, melanin-containing cells that are responsible for pigmentation and protection against UV DNA damage, and it is a tumor with rising incidence worldwide (Siegel et al., 2012). Although CM is curable by surgical resection if detected in the early stages (Breslow Index <2 mm depth), once it metastasizes its prognosis worsens, and it is refractory in the long-term to most current therapies (Gray-Schopfer et al., 2007). Different lines of evidence suggested that CM is an immunogenic tumor, mainly demonstrated by the existence of regressions in primary tumors and by the correlation between the presence of “brisk” lymphocytic infiltrates in primary tumors and longer survival (Clemente et al., 1996). Early work on CM vaccines was performed by Morton et al. (1968, 1970), Seigler et al. (1975), and by Berd and Mastrangelo (1988a,b), who used autologous irradiated melanoma cells as vaccines. After these pioneer attempts, several melanocytic differentiation Ag (MD-Ag) were discovered, such as MelanA/MART-1 (MART-1; Coulie et al., 1994; Kawakami et al., 1994a), gp100/PMEL17/silver (gp100; Kawakami et al., 1994b), tyrosinase (Brichard et al., 1993); tyrosinase-related protein-2 (trp-2; Wang et al., 1996), MELOE-1 (Godet et al., 2008), and a group of cancer-testis Ag (CT-Ag), such as the MAGE super-family and NY-ESO-1 (van der Bruggen et al., 1991; Chen et al., 1997). Besides these Ag, recent genomic work performed in human CM revealed dozens of mutations present in the melanoma genome, many of them residing in exons (Chin et al., 2006; Dutton-Regester and Hayward, 2012). The development of new high-throughput technologies, such as next-generation sequencing, will lead to a better knowledge of the battery of mutations present in different types of cancer and, particularly, in each patient. Somatic mutations that occur with very low frequencies may be detected, as well as other types of aberrations, including translocations and epigenetic changes (Ross and Cronin, 2011). Castle et al. (2012) identified somatic point mutations in B16F10 murine melanoma cell line using next-generation sequencing. Immunogenicity of 50 validated mutations was assayed by immunizing mice with peptides encoding for the mutated epitopes, founding that one third of them were immunogenic.

Therefore, and considering the failure of most chemotherapeutic treatments, immunotherapy presents as a promising option. Until recently, the still fully unanswered question was whether humoral or cellular immune response would be more convenient to eradicate tumors in general and CM in particular. In a phase III randomized clinical study performed in 880 CM patients, a vaccine of GM2 ganglioside coupled to Keyhole Limpet Hemo-cyanin and using QS-21 as adjuvant, which induced IgM and IgG antibodies, was compared with high-dose interferon-alfa. The vaccination arm did worse than the interferon arm, and the assay was interrupted before completion (Kirkwood et al., 2001). However, when the effort was placed in the stimulation of cellular immunity,
Ag-positive tumor cells, since we and others have shown that Ag-to be potent stimulators of naïve lymphocytes (Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be captured by dendritic cells (DC), first described by Steinman and Cohn (1973) in murine lymphoid organs, and later found to be capturing Ag in the periphery; (ii) maturation and migration of DC to draining lymph nodes; (iii) settling of DC in the lymph nodes and activation of naive lymphocytes. Some of these steps have been analyzed to some detail in mice, although evidence in humans is still lacking. Thus, Eggert et al. (1999) demonstrated that only about 1% of subcutaneously injected DC migrate to lymph nodes, although resident Langerhans cells, after immunization in vivo, migrate in high numbers to lymph nodes and persist there for about 2 weeks (Garg et al., 2003). It may be thus concluded that in vivo migration of DC is substantially more efficient than migration after DC production in vitro and subcutaneous injection, which could hamper vaccination attempts with DC loaded with tumor Ag. After this scarce migration of injected DC to regional lymph nodes, they must still overcome another difficulty: to find the appropriate T cells expressing the adequate TCR while maintaining bound to their HLA molecules the Ag peptides long enough to induce long-lasting contacts (Hugues et al., 2004). In fact, a clinical study comparing DC charged with tumor peptides or cell lysates demonstrated that only the latter were capable of inducing immune responses (Hersey et al., 2004). An explanation for these results came recently, since it has been shown that Ag peptides induced a quicker and stronger, but less prolonged response, than larger Ag peptides that are taken up by DC and degraded inside the cells (Faure et al., 2009). Recently, several approaches have taken profit of the ability of DC to capture foreign Ag, among them tumor Ag, and present them to naive lymphocytes (Goldszmid et al., 2003; Liu et al., 2005). In humans, Palucka et al. (2006) demonstrated that autologous DC were able to capture killed cells from an allogeneic tumor cell line and induce CD8+-T cell responses in 20 stage IV CM patients, leading to one complete and one partial response. Our group has demonstrated that autologous DC could capture a mixture of apoptotic and necrotic allogeneic melanoma cells, subsequently mature and cross-present MD-Ag to CD8 T cell clones (von Euw et al., 2007). von Euw et al. (2008) also performed a clinical study in CM patients demonstrating that up to 1% anti-MART-1 and anti-gp100 CD8 T cell lymphocytes could be found in circulating blood after vaccination. Although 80% of Stage III patients attained a disease-free survival longer than 116 months, all stage IV patients relapsed. None of the approaches used so far could demonstrate that injected DC charged with apoptotic/necrotic tumor cells in humans are able to migrate efficiently to draining lymph nodes and establish a correct communication with naive lymphocytes. The duration of the in vivo tumor Ag exposure by DC has also not been thoroughly studied in humans, as well as the number of CD8 cytotoxic T cells formed. A selection of different completed phase III clinical trials consisting in immunotherapeutic approaches against melanoma is shown in Table 1.
Table 1 | Immunotherapies against cancer: completed phase III clinical trials in CM.

| Type of treatment | Type of cancer | Clinical trial phase | Adjuvants used | Clinical results obtained | Reference |
|-------------------|----------------|----------------------|----------------|--------------------------|-----------|
| Ganglioside vaccine | Melanoma stages IIb/III | III | KLH – OS-21 | PFS and OS benefit with HDI vs. GMK | Kirkwood et al. (2001) |
| Peptide vaccines | Melanoma stage IV and unetectable stage III | III | IFA (Montanide ISA 51) | Longer PFS vs. high dose IL-2, no significant improvement in OS | Schwartzentruber et al. (2011) |
| Vitespen (autologous tumor-derived heat shock protein gp96 peptide complex vaccine) NCT00039000 | Melanoma stage IV | III | None | No changes in OS vs. physician choice | Testori et al. (2008) |
| Whole cell vaccines | Melanoma stage IV | III | BCG | No change in OS vs. BCG | Commented in Sondak et al. (2006), Dalgleish (2011) |
| CTLA-4 | Melanoma stage IV and unetectable stage III | III | IFA (Montanide ISA-51) in vaccine groups | Improved OS with ipilimumab alone or +gp100 vs. gp100 alone | Hodi et al. (2010) |
| Ipilimumab vs. placebo + dacarbazine | Melanoma stage IV and unetectable stage III | III | None | Longer OS with ipilimumab + dacarbazine | Robert et al. (2011) |

PFS, progression free survival; OS, overall survival.

Up to date, the only vaccine approved for cancer treatment is Provenge (sipuleucel-T), a vaccine for advanced prostate cancer which consists of a mixture of peripheral blood mononuclear cells exposed to prostatic acid phosphatase fused to GM-CSF. In a phase III clinical trial, the use of Provenge prolonged overall survival in patients with metastatic castration-resistant prostate cancer (Kantoff et al., 2010), but no effect on time to disease progression was observed. Provenge hypothesized mechanism for antitumor activity is that Ag-presenting cells (APC) process and present the recombinant Ag on their surface. After being reinfused into the patient, these cells could activate T cells that recognize the specific Ag and, therefore, stimulate them to attack prostatic acid phosphatase-positive prostate cancer cells (Sonpavde et al., 2012). This proposed mechanism requires further validation. There are several critiques to this vaccine related with the fact that improved overall survival was not accompanied with measurable antitumor effect and with the lack of supportive evidence for the mechanism proposed. After reanalysis of phase III data and of previously unpublished data obtained from FDA documents, Huber et al. (2012) made some concerns about this recently approved vaccine. In the first place, unexpected interactions between patient age and survival were found: an 11-month difference in median overall survival between placebo patients younger and older than 65 years was observed, and sipuleucel-T treatment appeared to have only a positive effect in survival of older patients. These results were unexpected because age is not a prognostic factor in castration-resistant prostate patients under chemotherapeutic treatment and immunotherapies should be more effective in younger patients. Other important point is that patients in the placebo group appeared to have shorter overall survival than might be expected from other studies, which led to think that placebo treatment is actually an inappropriate control for sipuleucel-T. Huber et al. also discussed the manufacture protocol of the vaccine and the placebo, suggesting that the placebo protocol included steps that could contribute to cell killing and therefore, injection of dead cells in patients of the placebo arm could lead to a reduction in overall survival (OS).

Besides this vaccine in particular, the reasons that could explain why therapeutic cancer vaccines do not act as well as expected are multiple. Finding the right adjuvants and countering immunosuppression are possible keys to bypass such limitations.

**ADJUVANTS**

A successful vaccination requires the addition to the desired Ag of adjuvants, which serve as amplifiers of the immune response. Adjuvants for clinical use must equilibrate efficacy with safety, although this balance should also integrate the purpose of vaccination: it is not the same scenario to vaccinate preventively millions of people against a viral disease such as influenza, than to vaccinate therapeutically a much more limited population with cancer, as would be the case of CM patients. In the latter case, a certain degree of toxicity of the adjuvants could be tolerated if the antitumor effect of vaccines is enhanced. We are still largely ignorant of the mechanism of action of adjuvants. The extremely potent complete Freund adjuvant (CFA) and incomplete Freund adjuvant (IFA) have been used for decades (Freund, 1956), but in spite of their potency, their use is not allowed in humans due to toxicity, since they may lead to harmful local injuries and...
autoimmune diseases. Essentially, IFA is paraffin oil suspended in water, and in addition, CFA contains heat-killed Mycobacteria, usually M. tuberculosis. Although used by immunologists for decades, the mechanisms of action of IFA and CFA are barely understood and are still being analyzed (Biliou and Matthys, 2001). Since IFA and CFA are potent but toxic, mineral oil has been replaced by terpenoids, among them the lipopholic substance squalene, a triterpene found in the adjuvants MF59 and AS03. Both have been used in clinical trials with a good safety profile and have been approved in Europe and conditionally approved in the US as stockpiled adjuvants in the pandemic influenza (Fox et al., 2011). Montanide™incomplete Seppic adjuvant (ISA) 51 and 720 are water-in-oil emulsions similar to IFA that are under investigation for their use in humans. Montanide™ISA 51 contains a manniide monooleate emulsifier and a degradable mineral oil, which has been demonstrated to be non-carcinogenic, non-teratogenic, and non-mutagenic. To improve safety, the mineral oil has been switched in Montanide™ISA 720 to the metabolizable squalene oil (Aucourturier et al., 2006).

Also, QS-21, a water-soluble triterpene glycoside, has been used in clinical trials (Soltysik et al., 1995; Livingston et al., 1997; Kensil and Kammer, 1998). Novel isoprenoid immunostimulants, such as those phytol-derived, are also being analyzed (Chowdhury and Ghosh, 2012).

Aluminum salt/gel-based (Alum) adjuvants are approved for clinical use in the US and have been used for many years as immunopotentiator for vaccines, being particularly effective to promote protective humoral immunity (Schijns and Lavelle, 2011). However, Alum adjuvants do not induce a T helper type 1 cell-mediated immune response.

A great input to understand the mechanism of action of adjuvants came after the seminal finding by Hoffman's group of the immune function of Toll receptors in flies (Lemaire et al., 1996). The identification of toll like receptors (TLR) in mammals, of which more than 10 different varieties are now recognized, paved the way to understand the importance of the innate immune response to Ag, and the subsequent interactions between the innate and adaptive immune system (Medzhitov et al., 1997). Specially important was the finding by Beutler's group that TLR4 recognizes pathogen-associated molecular patterns (PAMPs) such as those present in the bacterial lipopolysaccharide (LPS; Poltorak et al., 1998). From that point on, the appropriate search and use of adjuvants has acquired a more rational approach (LPS; Poltorak et al., 1998). From that point on, the appropri-ate search and use of adjuvants has acquired a more rational approach (LPS; Poltorak et al., 1998). From that point on, the appropri-ate search and use of adjuvants has acquired a more rational approach (LPS; Poltorak et al., 1998). From that point on, the appropri-ate search and use of adjuvants has acquired a more rational approach (LPS; Poltorak et al., 1998). From that point on, the appropri-ate search and use of adjuvants has acquired a more rational approach (LPS; Poltorak et al., 1998). From that point on, the appropri-
advit. CTLA-4 has an inhibitory role in T cell activation, and its expression and localization are tightly regulated in T cells. After activation, CTLA-4 expression increases, reaching a maximum after 2–3 days, and it is translocated to its active localization at the cell surface (Egen et al., 2002). CTLA-4 function is essential to the maintenance of immune homeostasis and helps tolerance to self Ag by downregulating T cell response and proliferation. CTLA-4-deficient mice die from profound lymphoproliferative disease, with multiorgan lymphocytic infiltration, and tissue destruction (Tivol et al., 1995; Waterhouse et al., 1995). However, mixed bone marrow chimeric mice that have both CTLA-4+/− and normal T cells do not present the lymphoproliferative disorder observed in CTLA-4-deficient mice (Bachmann et al., 1999), suggesting that CTLA-4 function has a non-cell autonomous component acting in trans. Different possibilities have been proposed to explain CTLA-4 mechanism of action. In the first place, CTLA-4 competes with CD28 for its ligands CD80 and CD86. Since both ligands have higher affinity for CTLA-4, it abolishes CD28 signaling, therefore mediating an indirect effect. Besides, CTLA-4 sends cell-intrinsic cis negative signals through its cytoplasmic domain, inhibiting different components of the cell cycle machinery (Greenwald et al., 2002) and blocking TCR and CD28 signaling (Teft et al., 2006). CTLA-4 may also function by disrupting the organization of molecules in the immune synapse (Chambers et al., 2001). Additional potential CTLA-4 functions include upregulation of indolamine 2,3-dioxygenase (IDO) activity in APCs via CD80 and CD86 and regulation of T cell adhesion to APCs (Schneider et al., 2005; Sansson and Walker, 2006). Besides, evidence in mice suggests that CTLA-4 is constitutively expressed in Treg and would mediate Treg immunosuppression (Takahashi et al., 2000; Wing et al., 2008), since blocking CTLA-4 in Treg restrain their ability to inhibit T effector cell proliferation (Peggs et al., 2009). Recently, another cell extrinsic mechanism for CTLA-4 function was proposed, suggesting that it participates in the removal of costimulatory ligands via trans-endocytosis (Qureshi et al., 2011).

Two different models have been proposed to integrate the stimulatory signals involved in T cell activation and CTLA-4 function, the threshold and the attenuation models (Chambers et al., 2001). According to the threshold model, CTLA-4 would increase the minimum requirements for T cell activation by setting a threshold for the quantity and/or quality of TCR signal and/or costimulatory signals (Egen et al., 2002). The attenuation model proposes that CTLA-4 would exert its inhibitory function after T cell stimulation once the cell already entered cycling, and CTLA-4 levels would depend on strength of TCR signal.

**CTLA-4 AS THERAPEUTIC TARGET**

Considering CTLA-4 key role in the regulation of T cell response, blocking antibodies have been developed in order to potentiate antitumor immune response. Ipilimumab, a human IgG1 monoclonal antibody (mAb) anti-CTLA-4, and Tremelimunab, another human IgG2 mAb anti-CTLA-4, were tested in clinical trials in patients with CM (Ascierto et al., 2011). By which mechanism CTLA-4 blocking antibodies exert their function is not completely clear. In murine models, CTLA-4 blockade leads to antitumor cytotoxicity, presenting an increased ratio of CD8:Treg in tumor infiltrates (Quezada et al., 2006). Recently it has been proposed that CTLA-4 blockade could enhance memory CD8 T cell response (Pedicord et al., 2011), which could be important in cancer therapy to improve tumor-specific memory CD8 T cells and develop durable antitumor responses. Several early stage clinical trials demonstrated that CTLA-4 blockade alone or in combination with other therapies, as vaccines or chemotherapies, can induce tumor regression in a minority of metastatic CM patients (Hodi et al., 2003; Attia et al., 2005; Ribas et al., 2005, 2009). Hodi et al. (2008) showed that biopsies of metastatic melanoma lesions after ipilimumab administration showed dense infiltration of CD8 T cells, and tumor necrosis correlated with the ratio of infiltrating CD8 T cells/FoxP3+ cells. Blockade of CTLA-4 would promote T cell proliferation in lymphoid organs that would subsequently lead to an increased T-cell infiltration in most patients (Ribas et al., 2010; Huang et al., 2011). However, tumor infiltration by T cells does not correlate with patient’s clinical response (Huang et al., 2011), suggesting that resistance to CTLA-4 blockade could depend on the immunosuppressive mechanisms that the tumor displays.

Last year, as a result of a phase III clinical trial (Hodi et al., 2010), USA FDA approved the use of ipilimumab for treatment of advanced metastatic CM. The antibody therapy, with or without gp100 peptide vaccine, showed improved overall survival compared to gp100 vaccine alone. Toxicity was found in patients treated with ipilimumab, including grades 3–4 immune-related adverse events (irAE) in 10–15% of patients.

Another phase III study of ipilimumab was performed in patients with previously untreated metastatic CM. In this case, ipilimumab in combination with dacarbazine was compared with dacarbazine plus placebo, showing improved overall survival with the antibody therapy (Robert et al., 2011). Remarkably, the time of ipilimumab to induce tumor remissions may take months, pointing to a different mechanism of action than most chemotherapeutic agents.

**OTHER INHIBITORY CORECEPTORS**

In addition, diverse targets are also being studied in order to potentiate antitumor immune response. Programmed (cell) death-1 (PD-1; CD279) is an inhibitory coreceptor which can be expressed in activated T cells, B cells, NK cells, activated monocytes, and DC (Keir et al., 2008). The ligands for PD-1, PD-L1 (B7-H1; CD274), and PD-L2 (B7-DC; CD273) are upregulated in response to inflammation. In fact, the major role of PD-1 is to limit the activity of T cells in the periphery during an inflammatory response to infection and autoimmunity (Topalian et al., 2012). The PD-1/PD-L1 pathway is important in the development of central and peripheral tolerance to exogenous Ag at sites of immune privilege, limiting the duration of the normal adaptive immune response (Folkl and Bienzle, 2010). Physiological functions of the PD pathway are altered in cancer (Okazaki and Honjo, 2007). Currently, there are four anti-PD-1 agents in clinical testing for cancer therapy: MDX-1106/BMS-936558/ONO-4538; CT-011; MK-3475, and AMP-224 (Topalian et al., 2012). MDX-1106 is a fully human IgG4 mAb that has been tested in a phase I clinical trial on 39 patients with treatment-refractory solid tumors. This mAb showed antitumor activity and was well tolerated. Pharmacodynamic studies indicated a sustained mean occupancy of around 70% on circulating...
T cells during 2 months. Approximately 12% of patients suffered grade ≥ 3 adverse clinical events (Brahmer et al., 2010). A randomized phase II study is currently undergoing to evaluate this mAb in metastatic renal cell carcinoma. CT-011, a humanized IgG1 mAb, was tested on 17 patients with advanced hematologic malignancies. This anti-PD-1 agent was generally well tolerated (Berger et al., 2008). CT-011 is currently undergoing a phase II clinical trial on metastatic renal cell carcinoma patients.

LOW-DOSE CYCLOPHOSPHAMIDE

Another way of countering immune suppression is to use low doses of the alkylating agent cyclophosphamide (CTX). Already Berd and Mastrangelo (1988b) utilized low-dose CTX (300 mg/sq m) to diminish immune suppression in CM patients. This immune-enhancing effect of CTX was afterward analyzed in several experimental systems and using different CTX doses. The results obtained, although positive, point to different mechanisms of action. Thus, Ghiringhelli et al. (2004) working on a rat colon carcinoma, demonstrated that a single injection of CTX (30 mg/kg) determined tumor rejection, and the authors attributed this effect to lymphodepletion of CD4+/CD25+ Treg. In the C57Bl/6J mice/B16 melanoma cells model, Nakahara et al. (2010) found that a single injection of CTX (150 mg/kg) induced a selective and profound depletion of resident CD8+ DC, and that such depletion diminished the activity of Treg and restored concomitant antitumor immunity. Pointing in the same direction, Radiojic et al. (2010) demonstrated that a single injection of CTX (200 mg/kg) in mice bearing CT26 colon carcinoma would enhance antitumor immunity by resetting DC homeostasis.

Clinical trials using CTX to enhance antitumor immunity are scarce. Ghiringhelli et al. (2007) used iterative low doses of CTX in advanced cancer patients and demonstrated a strong reduction of circulating Treg. However, Ellebaek et al. (2012) in a phase II trial with CM patients using metronomic CTX, did not find any reduction in circulating Treg. Further clinical trials addressing the role of CTX to enhance antitumor immunity should be examined in carefully designed clinical trials.

WHICH SLEEPING LYMPHOCYTES NEED TO BE AWAKEN TO EXERT ANTITUMOR EFFECT?

After the observed induction by anti-CTLA-4 mAb of immune responses against tumors, as well as of autoimmune reactions, the question may be posed if such effects are due to the emergence of effector T lymphocytes induced de novo by the derepression of Treg on APC, or, alternatively, if CD4 and CD8 effector lymphocytes which are blocked in cis by CTLA-4 are already in the circulation and relieved from this suppression by ipilimumab. Besides, there is yet another question that remains to be answered: CD4 and CD8 cells generated by vaccination absolutely need to have high affinity or avidity toward tumor cells to be active? In this sense, it is important to note that Dutoit et al. (2002) have shown that in preimmune HLA-A2 individuals, up to 1/1,000 CD8 lymphocytes recognized MART-1 peptides with low avidity (nM range), as compared to high affinities found for TCR directed to viral Ag (pM range), and that most of the CD8 clones exhibited cross-reactivity toward self-peptides (TCR polyspecificity; Dutoit et al., 2002). However, expansion of the naïve anti-MART-1 CD8 pool does not appear to play a role in tumor regressions induced by ipilimumab, since the outcome of the naïve anti-MART-1 CD8 pool does not appear to play a role in tumor regressions induced by ipilimumab, since the outcome of HLA-A2-positive and -negative patients is similar (Wolchok et al., 2010). The polyspecificity of TCR has been studied in more detail in autoimmunity, in which several experimental models are available. In multiple sclerosis and Type 1 Diabetes, polyspecificity of the TCR, characterized by the ability of a single TCR to recognize diverse MHC-peptides, appears to be an intrinsic property of TCR (Liblau et al., 2011).

In the case of cancer, it is not yet known which are the TCR best suited to eliminate tumors in the long range: those with high affinity for a single HLA–peptide complex or those with medium affinity but directed against a variety of targets.

Another question that may be posed is the effective ability of CD8 T cells to lyse tumor cells. In this sense, the different contexts in which tumor cells and T lymphocytes may encounter should be differentiated. In the simplest case, that is, when cytotoxic lymphocytes (CTL) are confronted in vitro to tumor cells, we have shown that clonogenic melanoma cells are effectively lysed by anti-MART-1 and/or anti-gp100 CTL (Aris et al., 2012). However, if such activity is maintained in vivo has not been answered. Large tumors (>2 cm) are presently considered as an organ, in which complex interactions between the tumor and stroma are established, and in which genomic instability and inflammation play substantial roles in favoring tumor progression. A complex array of immunosuppressive factors is released by tumor cells, building an immunoresistant superstructure (Hanahan and Weinberg, 2000). It is our view that large tumors display a setting in which vaccination has a limited role; the most amenable clinical context to assay antitumor vaccination, would be patients in which the existence of micrometastasis is highly probable. Under such circumstances, the tumor “fortress” building has not been completed, and the immune system has fewer obstacles to surmount. CM patients with stages II and III of the disease could benefit from such therapy. The use of agents which counter immunosuppression, such as ipilimumab, in combination with cancer vaccines, could lead to additive or synergistic responses.

ACKNOWLEDGMENTS

This work has been supported by grants from the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT), Fundación Sales, Fundación Cáncer (FUCA), Fundación Pedro F. Mosoteuy, and Fundación María Calderón de la Barca, Argentina. José Mor-doh is a member of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), María Laura Laacre is a fellow of ANPCyT, and Florencia Paula Madorsky-Rowdo is a fellow of CONICET.
The tyrosine kinase genes code for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178, 489–495.

Castle, J. C., Kreiter, S., Diekmann, J., Lower, M., Van De Roemer, N., De Graaf, J., Selmi, A., Diken, M., Boegel, S., Paret, C., Koslowski, M., Kuhn, A. N., Britten, C. M., Huber, C., Tureci, O., and Sahin, U. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091.

Cesana, G. C., Derafelle, G., Cohen, S., Moroziewicz, D., Mitcham, J., Stoutenburg, J., Cheung, K., Hesdorffer, C., Kim-Schulze, S., and Kaufman, H. L. (2006). Characterization of CD4+C12D25+ regulatory T cells in primary melanomas and advanced hematologic malignancies. Ann. Rev. Immunol. 19, 565–594.

Chattopadhyay, S., Chakraborty, N. G., and Mukherji, B. (2005). Regulatory T cells and tumor immunity. Cancer Immunol. Immunother. 54, 1153–1161.

Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U.S.A. 94, 1911–1918.

Chin, L., Garraway, L. A., and Fisher, D. E. (2006). Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20, 2149–2182.

Cowdroy, R., and Ghosh, S. (2012). Phylotyped novel isoprenoid immunostimulant. Front. Immunol. 3:49. doi:10.3389/fimmu.2012.00049

Clement, C. G., Mihm, M. C., Jr., Bufalino, R., Zurrilla, S., Collini, P., and Cascinelli, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303–1310.

Correll, A., Tuettenberg, A., Becker, C., and Jonuleit, H. (2010). Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination. Exp. Dermatol. 19, e213–e221.

Coulie, P. G., Brichard, V., Van Pel, A., Wolfff, T., Schneider, I., Tavera-Savers, C., Mattie, S., De Plaen, E., Lurquin, C., Szikora, I. P., Renaud, I. C., and Boon, T. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180, 35–42.

Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Diis, M. L., Knutson, K. L., Chen, L., and Zou, W. (2004). Specific requirement of regulatory T cells in ovarian carcinoma: immune privilege or disease progression? Nat. Med. 10, 942–949.

Dalgleish, A. G. (2011). Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 29, 8501–8505.

Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90, 3539–3543.

Duthie, M. S., Windish, H. P., Fox, C. B., and Reed, S. G. (2011). Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239, 178–196.

Dutoit, V., Rubbo-Godoy, V., Pettit, M. J., Zippelius, A., Dietrich, F. Y., Legal, F. A., Guillaume, P., Romero, P., Cerottini, J. C., Houghten, R. A., Pinilla, C., and Valmori, D. (2002). Degeneracy of antigen recognition as the molecular basis for the high frequency of naive α2/Melan-a peptide multi-mer (+ CD8+) T cells in humans. J. Exp. Med. 196, 207–216.

Dutton, R. R., O'Reilly, K., and Hayward, N. K. (2012). Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell Melanoma Res. 25, 144–154.

Egen, J. G., Kuhns, M. S., and Jonuleit, H. (2010). Increased regulatory T cells in ovariann carcino noma fosters immune privilege and predicts reduced survival. Nat. Med. 16, 942–949.

Ellebaek, E., Engell-Noerregaard, L., Iversen, T. Z., Froesig, T. M., Munir, S., Hadrup, S. R., Andersen, M. H., and Svane, I. M. (2012). Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol. Immunother. doi:10.1007/s00262-012-1124-4.

Faure, E., Mantegazza, A., Sadaka, C., Sedlik, C., Zetorea, E., and Amigorena, S. (2009). Long-lasting cancer regression in human DC. Eur. J. Immunol. 39, 380–390.

Foley, E. J. (1953). Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13, 835–837.

Folkli, A., and Bienen, D. (2010). Structure and function of programmed death (PD) molecules. Vet. Immunol. Immunopathol. 134, 33–38.

Fontenot, J. D., Gavin, M. A., and Rudensky, A. Y. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330–336.

Fourcade, J., Sun, Z., Kadeka, E., Janiec, B., Kirkwood, J. M., El-Hafiawy, T., and Zarour, H. M. (2010). Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J. Immunol. 184, 6709–6718.

Fox, C. B., Baldwin, S. L., Duthie, M. S., Reed, S. G., and Vedvick, T. S. (2011). Immunomodulatory and physical effects of oil composition in vaccine adjuvant emulsions. Vaccine 29, 9563–9572.

Freund, J. (1956). The mode of action of immunologic adjuvants. Bibl. Tuberc. 10, 130–148.

Garb, S., Oran, A., Wajchman, J., Sasaki, S., Maris, C. H., Kapp, J. A., and Jacob, J. (2003). Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat. Immunol. 4, 907–912.

Ghirgihelli, F., Larmion, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., and Martin, E. (2004). CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of...
Hillen, F., Baeten, C. I., Van De Winkel, Hersey, P., Menzies, S. W., Hall-Francis, Madorsky-Rowdo et al. Immune system and cancer control
Goldszmid, R. S., Idoyaga, J., Bravo, A. van Der Woude, D., Kubal, A., Man-A., Macrae, S., Nelson, M., Canning, G. (2008). Immunologic and clinical parameters of aggressiveness in patients with disseminated melanoma.
Goldstein, J. P., Mihm, M. C., and Dranoff, C., Lowy, I., Korman, A., Lautz, D., den, M. V., Haluska, F. G., Kruse, F., Jotereau, F., and Labarriere, N. (2008). MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency. J. Exp. Med. 205, 2673–2682.
Goldstein, J. P., S. I., Idoyaga, J., Bravo, A. L., Steinman, R., Morodoh, J., and Wainstok, R. (2003). Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J. Immunol. 171, 5940–5947.
Gray-Schopfer, V., Wellbrock, C., and Marais, R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851–857.
Greenwald, R. J., Oosterwegel, M. A., Van Der Woude, D., Kubal, A., Mandelbrot, D. A., Boussetovit, A. S., and Sharpe, A. H. (2002). CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 32, 366–373.
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57–70.
Hersey, P., Menzies, S. W., Halliday, G. M., Nguyen, T., Farrelly, M. L., Desilva, C., and Lett, M. (2004). Phase I/II study of treatment with dendritic cell vaccine in patients with disseminated melanoma. Cancer Immunol. Immunother. 53, 125–134.
Hillen, F., Baeten, C. I., Van De Winkel, A., Creyten, D., Van Der Schaft, D. W., Winnenpennicks, V., and Griffioen, A. W. (2008). Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. Cancer Immunol. Immunother. 57, 97–106.
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, J., Korman, A., Lautz, D., Russell, R., Jaklitsch, M. T., Ramayya, N., Chen, T. C., Neuberg, D., Allison, J. P., Mihm, M. C., and Dranoff, G. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. U.S.A. 105, 3085–3090.
Hodi, F. S., Milam, M. C., Soffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., Macae, S., Willman, A., Padera, R., Jaklitsch, M. T., Shankar, S., Chen, T. C., Korman, A., Allison, J. P., and Dranoff, G. (2003). Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U.S.A. 100, 4712–4717.
Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Somson, J. A., Haarh, J. B., Gonzales, R., Siper, R. B., Xu, Y., Frohlich, M. W., and Schellhammer, P. F. (2010). Ipilimumab immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422.
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. E., Rivoltini, L., Topalian, S. L., Miki, T., and Rosenberg, S. A. (1994a). Cloning of the gene encoding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. U.S.A. 91, 3515–3519.
Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. (1994b). Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. U.S.A. 91, 6458–6462.
Keir, M. E., Butte, M. J., Freeman, G. J., and Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704.
Kensil, C. R., and Kammer, R. (1998). QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs 7, 1473–1482.
Kawakami, Y., Miyahara, Y., Wang, H. Y., Peng, W., Werker, R. J., Livingston, P., Zhang, S., Adluri, S., Yao, T. J., Graeber, L., Rugaupghi, G., Helling, E., and Fleisher, M. (1997). Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH. J. Immunother. 20, 34–40.
Kodell, R. L., Vermy, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., and Schreiber, R. D. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907.
Landay, A., Mohos, A., Somlai, B., Liszkyay, G., Gilde, K., Fejos, Z., Gaudi, I., and Timar, J. (2010). FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma. Pathol. Oncol. Res. 16, 303–309.
Lemaire, B., Nicolas, E., Michaut, L., Reichhart, J. M., and Hoffmann, J. A. (1996). The dorsoventral regulatory gene cassette spatz/Toll/irr controls the potent antifungal response in Drosophila adults. Cell 86, 973–983.
Liblau, R., Wekerle, H., and Tisch, R. (2011). Cumulative autoimmune: T-cell clones recognizing several self-epitopes exhibit enhanced pathogenicity. Front. Immunol. 2:47. doi:10.3389/fimmu.2011.00047.
Liu, K., Idoyaga, J., Charalambous, S. A., Fujii, S., Bonito, A., Morodoh, J., Wainstok, R., Bai, X. F., Liu, Y., and Steinman, R. M. (2005). Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J. Exp. Med. 202, 1507–1516.
Livingston, P., Zhang, S., Adluri, S., Yao, T. J., Graeber, L., Rugaupghi, G., Helling, E., and Fleisher, M. (1997). Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH. J. Immunother. 20, 34–40.
Losert, K., and Beissert, S. (2012). Regulatory T cells: banned cells for decades. J. Invest. Dermatol. 132, 864–871.
Luiten, R. M., Kueter, E. W., Mooi, W., Gallee, M. P., Rankin, E. M., Gerritsen, W. R., Cliff, S. M., Noon-ten, W. J., Wieder, R., Van De Kaste, W. F., S., F. J., Van Der Berk, P. C., Nieweg, O. E., Berns, A. M., Spits, H., and De Gast, G. C. (2005). Immunogenicity, including...
vitality, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23, 8978–8991.

Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A. Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394–397.

Miracco, C., Mourmouras, V., Biagioli, M., Rubeghi, P., Mannucci, S., Monciatti, L., Cosci, E., Tosi, P., and Luzi, P. (2007). Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol. Rep. 18, 1115–1122.

Montonen, O., Junttila, R. R., Joseph, W. L., Wood, W. C., Trahan, E., and Ketcham, A. S. (1970). Immunological factors in human sarcomas and melanomas: a rational basis for preimmunotherapy. Ann. Surg. 172, 740–749.

Morton, D. L., Malmgren, R. A., Holmes, E. C., and Ketcham, A. S. (1968). Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64, 233–240.

Nair, S., Boczowski, D., Fassnacht, M., Pisetsky, D., and Gilboa, E. (2007). Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67, 371–380.

Nakahara, T., Uchi, H., Lesokhin, A. M., Avagord, E., Rizzuto, G. A., Hirschhorn-Cymerman, D., Panageas, K. S., Merghub, T., Wolchok, J. D., and Houghton, A. N. (2010). Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 115, 4384–4392.

Okazaki, T., and Honjo, T. (2007). PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813–824.

Palucka, A. K., Ueno, H., Connolly, J., Kerneis-Norvell, F., Blanck, J. P., Johnston, D. A., Fay, I., and Banchereau, J. (2006). Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J. Immunother. 29, 545–557.

Pedicord, V. A., Montalvo, W., Leiner, I. M., and Allison, J. P. (2011). Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc. Natl. Acad. Sci. U.S.A. 108, 266–271.
role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol. 61, 639–647.

Steinman, R. M., and Cohn, Z. A. (1973). Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantita-
tion, tissue distribution. J. Exp. Med. 137, 1142–1162.

Steinman, R. M., and Witmer, M. D. (1978). Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc. Natl. Acad. Sci. U.S.A. 75, 5132–5136.

Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., and Whiteside, T. L. (2007). A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 13, 4345–4354.

Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., and Sakaguchi, S. (2000). Immunologic self-tolerance main-
tained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192, 303–310.

Teff, W. A., Kirchhoff, M. G., and Madrenas, J. (2006). A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24, 65–97.

Terando, A. M., Faries, M. B., and Mort-
ton, D. L. (2007). Vaccine therapy for melanoma: current status and future directions. Vaccine 25(Suppl. 2), B4–B16.

Testori, A., Richards, J., Whitman, E., Mann, G. B., Lutjky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., Yuh, L., Gupta, R., and Srivastava, P. K. (2008). Phase II comparison of vitespen, an autolo-
gous tumor-derived heat shock pro-
tein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100- 21 study group. J. Clin. Oncol. 26, 955–962.

Tivol, E. A., Borrelli, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., and Sharpe, A. H. (1995). Loss of CTLA-4 leads to massive lym-
phoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Immunity 3, 541–547.

Topalian, S. L., Drake, C. G., and Par-
doll, D. M. (2012). Targeting the PD-1/B7-H1 (PD-L1) pathway to acti-
vate anti-tumor immunity. Curr. Opin. Immunol. 24, 207–212.

Trumpfeller, C., Caskey, M., Nchinda, G., Longhi, M. P., Mizzena, O., Huang, Y., Schlesinger, S. J., Colonna, M., and Steinman, R. M. (2008). The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl. Acad. Sci. U.S.A. 105, 2574–2579.

van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van Den Eynde, B., Knuth, A., and Boon, T. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647.

Vence, L., Palucka, A. K., Fay, J. W., Ito, T., Liu, Y. J., Blanchereau, J., and Ueno, H. (2007). Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U.S.A. 104, 20884–20889.

von Euw, E. M., Barrio, M. M., Furman, D., Bianchini, M., Levy, E. M., Yee, C., Li, Y., Wainstok, R., and Mordoh, J. (2007). Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J. Transl. Med. 5, 19.

von Euw, E. M., Barrio, M. M., Fur-
man, D., Levy, E. M., Bianchini, M., Peguillet, L., Lantz, O., Velice, A., Kohan, A., Chacon, M., Yee, C., Wainstok, R., and Mordoh, J. (2008). A phase I clinical study of vacci-
nation of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J. Transl. Med. 6, 6.

Wang, H. Y., Lee, D. A., Peng, G., Guo, Z., Li, Y., Kiniwa, Y., Shevach, E. M., and Wang, R. F. (2004). Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107–118.

Wang, R. F., Appella, E., Kawakami, Y., Kang, X., and Rosenberg, S. A. (1996). Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184, 2207–2216.

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Grierer, H., and Mak, T. W. (1995). Lymphoprolifera-
tive disorders with early lethal-
ity in mice deficient in Cta-4. Science 270, 985–988.

Whiteside, T. L. (2012). What are regula-
tory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6, 295–307.

Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could be construed as a potential con-
fl ict of interest.

Received: 24 February 2012; accepted: 16 April 2012; published online: 04 May 2012.

Citation: Madorsky-Rwondo FP, Lacan ML and Mordoh J (2012) Melanoma vac-
cines and modulation of the immune system in the clinical setting: building from new realities. Front. Immunol. 3:103. doi: 10.3389/fimmu.2012.00103

This article was submitted to Frontiers in Immunotherapies and Vaccines, a spe-
cialty of Frontiers in Immunology.

Copyright © 2012 Madorsky-Rwondo, Lacan and Mordoh. This is an open-acess article distributed under the terms of the Creative Commons Attribution Non Commercial License, which per-
mits non-commercial use, distribution, and reproduction in other forums, pro-
vided the original authors and source are credited.